Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.

Implementation Medication for opioid use disorder (MOUD) Opioid use disorder (OUD) Primary care Rural health Telemedicine (TM)

Journal

Journal of substance use and addiction treatment
ISSN: 2949-8759
Titre abrégé: J Subst Use Addict Treat
Pays: United States
ID NLM: 9918541186406676

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 23 01 2023
revised: 11 04 2023
accepted: 16 10 2023
medline: 4 12 2023
pubmed: 21 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

Opioid overdose deaths are increasing rapidly in the United States. Medications for opioid use disorder (MOUD) are effective and can be delivered in primary care, but uptake has been limited in rural communities. Referral to and coordination with an external telemedicine (TM) vendor by rural primary care clinics for MOUD (TM-MOUD) may increase MOUD access for rural patients, but we know little about perspectives on this model among key stakeholders. As part of a TM-MOUD feasibility study, we explored TM-MOUD acceptability and feasibility among personnel and patients from seven rural primary care clinics and a TM-MOUD vendor. We conducted virtual interviews or focus groups with clinic administrators (n = 7 interviews), clinic primary care and behavioral health providers (8 groups, n = 30), other clinic staff (9 groups, n = 37), patients receiving MOUD (n = 16 interviews), TM-MOUD vendor staff (n = 4 interviews), and vendor-affiliated behavioral health and prescribing providers (n = 17 interviews). We asked about experiences with and acceptability of MOUD (primarily buprenorphine) and telemedicine (TM) and a TM-MOUD referral and coordination model. We conducted content analysis to identify themes and participants quantitatively rated acceptability of TM-MOUD elements on a 4-item scale. Perceived benefits of vendor-based TM-MOUD included reduced logistical barriers, more privacy and less stigma, and access to services not available locally (e.g., counseling, pain management). Barriers included lack of internet or poor connectivity in patients' homes, limited communication and trust between TM-MOUD and clinic providers, and questions about the value to the clinic of TM-MOUD referral to external vendor. Acceptability ratings for TM-MOUD were generally high; they were lowest among frontline staff. Rural primary care clinic personnel, TM-MOUD vendor personnel, and patients generally perceived referral from primary care to a TM-MOUD vendor to hold potential for increasing access to MOUD in rural communities. Increasing TM-MOUD uptake requires buy-in and understanding among staff of the TM-MOUD workflow, TM services offered, requirements for patients, advantages over clinic-based or TM services from clinic providers, and identification of appropriate patients. Poverty, along with patient hesitation to initiate treatment, creates substantial barriers to MOUD treatment generally; insufficient internet availability creates a substantial barrier to TM-MOUD.

Identifiants

pubmed: 37863356
pii: S2949-8759(23)00245-X
doi: 10.1016/j.josat.2023.209194
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

209194

Subventions

Organisme : NIDA NIH HHS
ID : UG1 DA040309
Pays : United States

Informations de copyright

Copyright © 2023 RAND Corporation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Allison J Ober (AJ)

RAND Corporation, Santa Monica, CA, USA. Electronic address: ober@rand.org.

Alex R Dopp (AR)

RAND Corporation, Santa Monica, CA, USA.

Sarah E Clingan (SE)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Megan E Curtis (ME)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Chunqing Lin (C)

Semel Institute for Neuroscience and Human Behavior, Center for Community Health, University of California at Los Angeles, CA, USA.

Stacy Calhoun (S)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Sherry Larkins (S)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Megan Black (M)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Maria Hanano (M)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Katie P Osterhage (KP)

Department of Family Medicine, University of Washington, Seattle, WA, USA.

Laura-Mae Baldwin (LM)

Department of Family Medicine, University of Washington, Seattle, WA, USA.

Andrew J Saxon (AJ)

Veterans Affairs Puget Sound Health Care System, USA; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.

Emily G Hichborn (EG)

Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.

Lisa A Marsch (LA)

Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA.

Larissa J Mooney (LJ)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Yih-Ing Hser (YI)

Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH